If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Data Management and Biostatics
Download FREE Excerpt
9 Info Graphics
24 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
The power of real world evidence (RWE) has significantly increased demand for outcomes and other RWE insights across the entire healthcare value chain, from thought leaders and HCPs to payers and regulatory bodies.
In response, pharmaceutical and medical device companies are taking steps to increase the precision and speed of their RWE capabilities. This trend has impacted Medical Affairs since pharma already relies on this function to lead many of the medical aspects of RWE utilization.
This study evaluates the role of Medical Affairs in real world evidence utilization, investment and performance measurement. This study will inform Medical Affairs leaders regarding the current trends and practices of medical regarding RWE utilization, investment and ROI.
1. Improvements to Medical Affairs’ use of real world data
Best Practices engaged 45 industry leaders across 36 companies to discern RWD/E best practices, trends, and Medical Affairs optimal role.
Pharmaceutical; Consumer Products; Health Care; Medical Device; Biotech; Biopharmaceutical; Clinical Research; Laboratories
Novartis; Merck; EMD Serono; Roche; AstraZeneca; Astellas; Merck Serono; Takeda Pharmaceuticals; Sanofi; Boehringer Ingelheim; Teva Pharmaceutical Industries Ltd; Eisai; Jazz Pharmaceuticals; Grifols; Edwards Lifesciences; OTSUKA; Vertex Pharmaceuticals; Terumo Corporation; UCB Pharma; Avanos Medical; GE Healthcare; Fidia; Intercept; CSPC Pharmaceutical Group; Invitae; Cipla; Proteus Digital Health; Agios; Almirall; Adamas Pharmaceuticals; Dendreon; Purdue Pharma; Searle; ADC Therapeutics; Mitsubishi Tanabe Pharma; Melinta Therapeutics; Inc
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.